Vascepa, known in Europe as Vazkepa, is a prescription medication used to treat adults with high levels of triglycerides in their blood. According to the European Medicines Agency (EMA) [3], the active substance in Vazkepa is icosapent ethyl, and it is available in capsule form.

Although the cost of Vazkepa in Europe is not explicitly mentioned in the provided sources, it is known that the medication was launched in Europe by Amarin in March 2021 [2]. Amarin is a pharmaceutical company based in Ireland, and they have stated that the launch of Vazkepa in Europe is a significant milestone for the company.

According to DrugPatentWatch [1], the patent for Vascepa expired in the United States in 2020, which may indicate that the cost of the medication in Europe could be lower than in the United States due to increased competition. However, it is important to note that pricing for medications can vary widely between countries due to a variety of factors, including regulatory requirements, manufacturing costs, and market demand.

In summary, the cost of Vazkepa in Europe is not explicitly mentioned in the provided sources. However, it is known that the medication was launched in Europe in March 2021 by Amarin, and it contains the active substance icosapent ethyl. While the expiration of the Vascepa patent in the United States may suggest that the cost of Vazkepa in Europe could be lower, pricing for medications can vary widely between countries.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/marketing/amarin-launches-vascepa-all-important-europe-as-blockbuster-to-be-heart-drug-slowly
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa